Nexalin Technology has secured a US patent related to its non-invasive, frequency-based deep brain stimulation device, Gen-3 HALO Clarity system.
Awarded by the United States Patent and Trademark Office (USPTO), the patent is entitled “Transcranial Alternating Current Dynamic Frequency Stimulation Method for Anxiety, Depression and Insomnia (ADI)”.
Related: Kelyniam and Finceramica announce FDA clearance for NEOS system
It covers the method of use for the device, which is designed to treat anxiety, depression, and insomnia (ADI), from the comfort of patients’ homes.
Nexalin Technology CEO Mark White said: “This method of use patent award marks a major achievement for the company and follows another recent patent covering our core technology.
“These patents extend through 2040 and are a critical element of our overall strategy, given the mounting clinical data supporting the benefits of our noninvasive, deep frequency brain stimulation technology in the fields of insomnia, depression, and anxiety.”
The Gen-3 HALO Clarity, which represents a significant advancement over the previous Gen-1 system, features Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) technology.
Using a digital breakthrough in electrical waveforms, the DIFS technology provides deep brain neural stimulation.
The non-invasive deep brain stimulation device operates through electrodes placed on the cranium, targeting brain regions associated with mental health.
White added: “A key differentiator for our new Gen-3 HALO Clarity is that, for the first time, it enables patients to receive this treatment in the privacy of their own homes with remote monitoring by a physician in Nexalin’s Virtual Clinic.
“Importantly, we are advancing our strategy for regulatory clearance in the US, while focusing on commercial rollout in a variety of overseas markets.”
Recently, Nexalin revealed positive data from a clinical trial that assessed its neurostimulation device in veteran patients with combat-related mild traumatic brain injury.
